MIRACLE study (CBCSG016): A randomized phase II study of letrozole versus letrozole plus everolimus for hormone receptor positive premenopausal women with recurrent or metastatic breast cancer on goserelin treatment after progession on tamoxifen. | |
Xu, Binghe; Liu, Donggeng; Lu, Jinsong; Ouyang, Tao; Li, Xiang; Fan, Ying | |
2015 | |
卷号 | 33期号:15 |
ISSN号 | 0732-183X |
URL标识 | 查看原文 |
收录类别 | SCIE |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/6386386 |
专题 | 中国医学科学院 北京协和医学院 |
推荐引用方式 GB/T 7714 | Xu, Binghe,Liu, Donggeng,Lu, Jinsong,et al. MIRACLE study (CBCSG016): A randomized phase II study of letrozole versus letrozole plus everolimus for hormone receptor positive premenopausal women with recurrent or metastatic breast cancer on goserelin treatment after progession on tamoxifen.[J],2015,33(15). |
APA | Xu, Binghe,Liu, Donggeng,Lu, Jinsong,Ouyang, Tao,Li, Xiang,&Fan, Ying.(2015).MIRACLE study (CBCSG016): A randomized phase II study of letrozole versus letrozole plus everolimus for hormone receptor positive premenopausal women with recurrent or metastatic breast cancer on goserelin treatment after progession on tamoxifen..,33(15). |
MLA | Xu, Binghe,et al."MIRACLE study (CBCSG016): A randomized phase II study of letrozole versus letrozole plus everolimus for hormone receptor positive premenopausal women with recurrent or metastatic breast cancer on goserelin treatment after progession on tamoxifen.".33.15(2015). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论